Factor VIII safety: Plasma-derived versus recombinant products

Blood Transfusion

Volumn 9, Issue 4, 2011, Pages 366-370

  Gringeri, Alessandro ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Factor VIII; Haemophilia A; Inhibitors; Plasma derived; Recombinant; Safety

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD DONOR; DRUG SAFETY; GENETIC ENGINEERING; HEMOPHILIA A; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOGENICITY; REVIEW;

FACTOR VIII; HEMOPHILIA A; HUMANS; PLASMA; RECOMBINANT PROTEINS; SAFETY;

EID: 80054883005     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2011.0092-10     Document Type: Review

References (42)

1. Pool JG, Gershgold EJ, Pappenhagen AR. Highpotency antihaemophilic factor concentrate prepared from cryoglobulin precipitate. Nature 1964; 203: 312.
2. Pool JG, Shannon AE. Production of high-potency concentrates of antihaemophilic globulin in a closedbag system. N Engl J Med 1965; 273: 1443-7.
3. Brinkhous KM, Shanbrom E, Roberts HR, et al. A new high-potency glycine-precipitated antihemophilic factor (AHF) concentrate. Treatment of classical hemophilia and hemophilia with inhibitors. JAMA 1968; 205: 613-7.
4. Centers for Disease Control and Prevention (CDC). Pneumocystis carinii pneumonia among persons with hemophilia A. MMWR Morb Mortal Wkly Rep 1982; 31: 365-7.
5. Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981; 305: 1425-31. (Pubitemid 12240076)
6. Popovic M, Sarngadharan MG, Read E, et al. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984; 224: 497-500. (Pubitemid 14134740)
7. Sarngadharan MG, Popovic M, Bruch L, et al. Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. Science 1984; 224: 506-8. (Pubitemid 14134743)
8. Yarchoan R, Klecker RW, Weinhold KJ, et al. Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 1986; 1: 575-80. (Pubitemid 16138382)
9. Rouzioux C, Chamaret S, Montagnier L, et al. Absence of antibodies to AIDS virus in haemophiliacs treated with heat-treated factor VIII concentrate. Lancet. 1985;1: 271-2. (Pubitemid 15170368)
10. Colombo M, Mannucci PM, Carnelli V, et al. Transmission of non-A, non-B hepatitis by heat-treated factor VIII concentrate. Lancet 1985; 2: 1-4.
11. Horowitz MS, Rooks C, Horowitz B, et al. Virus safety of solvent/detergent-treated antihaemophilic factor concentrate. Lancet 1988; 2: 186-9.
12. Tabor E. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 1999; 39: 1160-8.
13. Centers for Disease Control and Prevention (CDC). Blood safety monitoring among persons with bleeding disorders-United States, May 1998-June 2002. MMWR Morb Mortal Wkly Rep 2003; 51: 1152-4.
14. Ironside JW, Head MW. Variant Creutzfeldt-Jakob disease: risk of transmission by blood and blood products. Haemophilia 2004; 10 (Suppl 4): 64-9. (Pubitemid 40045421)
15. Toole JJ, Knopf JL, Wozney JM, et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312: 342-7. (Pubitemid 15209311)
16. Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature 1984; 312: 326-30. (Pubitemid 15209308)
17. Vehar GA, Keyt B, Eaton D, et al. Structure of human factor VIII. Nature. 1984; 312: 337-42. (Pubitemid 15209310)
18. Wood WI, Capon DJ, Simonsen CC, et al. Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312: 330-7. (Pubitemid 15209309)
19. White GC 2nd, McMillan CW, Kingdon HS, et al. Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia. N Engl J Med 1989; 320: 166-70. (Pubitemid 19033095)
20. Mannucci PM. Back to the future: a recent history of haemophilia treatment. Haemophilia 2008; 14(Suppl 3): 10-8. (Pubitemid 351722377)
21. http://www.ukhcdo.org/docs/Annual%20Report%20 2007%20slides.pdf. Accessed on 30/09/2010.
22. Gringeri A, Mantovani LG, Scalone L, et al. for the COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-63. (Pubitemid 37193570)
23. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35. (Pubitemid 36874391)
24. Lorenzo JI, Lopez A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol 2001; 113: 600-3. (Pubitemid 32524377)
25. Ehrenforth S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
26. Addiego JE, Kasper C, Abildgaard C, et al. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet 1993; 342: 462-4. (Pubitemid 23240310)
27. Schimpf K, Schwarz P, Kunschak M. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex. Thromb Haemost 1995; 73: 553-5.
28. Guerois C, Laurian Y, Rothschild C, et al. Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate. Thromb Haemost 1995; 73: 215-8.
29. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993; 328: 453-9. (Pubitemid 23056434)
30. Rothschild C, Laurian Y, Satre EP, et al. French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII : incidence of inhibitor and evaluation of immune tolerance. Thromb Haemost 1998; 80: 779-83. (Pubitemid 28521722)
31. Kreuz W, Gill JC, Rothschild C, et al. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation. Thromb Haemost 2005; 93: 457-67. (Pubitemid 40392533)
32. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients. Semin Hematol 2001; 38(2 Suppl 4): 52-9. (Pubitemid 32618681)
33. Scharrer I, Ehrlich HJ. Reported inhibitor incidence in FVIII PUP studies: comparing apples with oranges? Haemophilia 2004; 10: 197-8. (Pubitemid 38312651)
34. Amano K, Arai M, Koshihara K, et al. Autoantibody to factor VIII that has less reactivity to factor VIII/von Willebrand factor complex. Am J Hematol 1995; 49: 310-7.
35. Auerswald G, Spranger T, Brackmann HH. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica 2003; 88: EREP05.
36. Gringeri A, Monzini M, Tagariello G, et al. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate. Haemophilia. 2006; 12: 128-32.
37. Goudemand J, Rothschild C, Demiguel V, et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46-51. (Pubitemid 43054971)
38. Gouw SC, van der Born JG, Auerswald G, et al. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007; 109: 4693-7. (Pubitemid 46827760)
39. Chalmers EA, Brown SA, Keeling D, et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia. 2007; 13: 149-55. (Pubitemid 46237946)
40. Iorio A, Halimeh S, Holzhauer S, et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost 2010; 8: 1256-65.
41. Mannucci PM. Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better. Blood Transfus 2010; 8: 288-91.
42. Franchini M. Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: recombinant is better. Blood Transfus 2010; 8: 292-6.